scholarly journals A comparative study of atorvastatin and rosuvastatin on lipid lowering efficacy in hyperlipidemic patients

2018 ◽  
Vol 11 (1) ◽  
pp. 17
Author(s):  
Samia Haque Tonu ◽  
Zesmin Fauzia Dewan ◽  
Nargis Akhter ◽  
Sajal Krishna Banerjee
Keyword(s):  
Lipid Profile ◽  
Serum Triglyceride ◽  
Lipid Lowering ◽  
Serum Triglyceride Level ◽  
Intergroup Difference ◽  
Atorvastatin Group ◽  
Significant Difference ◽  
Rosuvastatin Group ◽  
Significant Change ◽  
Lipid Lowering Effect

<p class="Abstract">The aim of the present study was to compare the lipid lowering effect of atorvastatin and rosuvastatin in patients (n=52) with hyperlipidemia. Patients were assigned to atorvastatin 10 mg or rosuvastatin 5 mg daily for 8 weeks. The blood was collected at baseline and after intervention to measure serum lipid profile. The level of serum total cholesterol in both atorvastatin and rosuvastatin groups was significantly reduced after intervention (p&lt;0.00001 and p&lt;0.00001 respectively) but no statistically significant difference (p=0.503) was observed between the two statin-treated groups. The reduction of serum triglyceride level was also significant (p=0.046 in atorvastatin group and p=0.0006 in rosuvastatin group). No significant difference was observed between the two groups (p=0.312). The serum LDL-C level was reduced significantly in both atorvastatin group (p&lt;0.00001) and rosuvastatin group (p&lt;0.00001). Again no statistically significant difference (p= 0.749) was observed between the two groups. No significant change was observed in the serum HDL level. Intergroup difference was not significant (p= 0.721). The present study indicates that, both atorvastatin and rosuvastatin improve the lipid profile but no significant change was observed between the two groups.</p>

scholarly journals Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia

2018 ◽  
Vol 8 (3) ◽  
pp. 153-158
Author(s):  
Samia Haque Tonu ◽  
Jesmine Fauzia Dewan ◽  
Fahmida Hasnat ◽  
Begum Rudaba Jahan
Keyword(s):  
Platelet Count ◽  
Serum Lipid ◽  
Thrombus Formation ◽  
Lipid Lowering ◽  
Atorvastatin Group ◽  
Beneficial Effects ◽  
Reductase Inhibitors ◽  
Significant Difference ◽  
Rosuvastatin Group ◽  
Coa Reductase

Background: Atorvastatin and rosuvastatin are two widely used HMG-CoA reductase inhibitors (statins). These are used as lipid-lowering drugs to reduce atherosclerosis-induced cardiovascular events. The beneficial effects of statins also involve some lipid-independent mechanisms which include modification of thrombus formation and degradation, alteration in inflammatory response, plaque stabilization and improvement of endothelial function.Objective: To compare antithrombogenic effect of atorvastatin and rosuvastatin in patients with hyperlipidemia.Materials and Methods: A prospective, open-labeled, interventional, randomized and single-center study was carried out in Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka from March, 2016 to August, 2017 on 52 hyperlipidemic patients. After randomization patients were assigned to atorvastatin 10 mg or rosuvastatin 5 mg daily for 8 weeks. Blood was collected at baseline and after intervention to measure platelet count, prothrombin time (PT) and serum lipid profile.Results: The baseline characteristics of patients treated with atorvastatin and rosuvastatin were almost identical. The platelet count in atorvastatin group was reduced after intervention (2.30%, p=0.463) which was not significant but in rosuvastatin group platelet count reduced significantly (12.33%, p=0.021) after intervention. There was no statistically significant difference (p=0.187) between the two statin treated groups. PT was increased significantly after intervention in both atorvastatin group (31.44%, p<0.001) and in rosuvastatin group (31.93%, p=0.003), which was statistically significant. No significant difference was observed between the two groups (p=0.573). Both atorvastatin and rosuvastatin significantly improved serum lipid profile.Conclusion: The present study reveals that rosuvastatin reduced thrombogenesis more effectively than atorvastatin in hyperlipidemic patients.J Enam Med Col 2018; 8(3): 153-158

Effects of selected herbal supplements in persons with type 2 diabetes

2020 ◽  
Vol 22 (4) ◽  
pp. 254-259
Author(s):  
Gajendra Prasad Rauniyar ◽  
R Sinha ◽  
DR Pandey ◽  
K Chapagain ◽  
R Maskey
Keyword(s):  
Lipid Profile ◽  
Blood Sugar ◽  
Serum Triglyceride ◽  
Multiple Comparisons ◽  
Lipid Lowering ◽  
Total Serum ◽  
Fenugreek Seeds ◽  
Group I ◽  
Significant Difference ◽  
Post Hoc

Diabetes mellitus is a metabolic abnormality leading to an increase in the plasma concentration of glucose and is a major cause of stroke and peripheral circulatory disorders. Momordica charantia (MC), commonly known as bitter gourd/Karela, and Trigonella foenum-graecum (TFG) (fenugreek/Methi) have several medicinal values like anti-diabetic, lipid-lowering property, anti-oxidant activity, anti-inflammatory, and anti-mutagenic activity. This is an open-label, four-parallel-group, prospective interventional clinical trial with a total number of 48 patients enrolled in the study and divided into four equal groups (12 in each group) viz; Group I (allopathic drug), Group II (allopathic drug and Karela (MC), Group III (allopathic drug and Methi (TFG) and Group IV (allopathic drug, methi, and karela). Blood sugar and lipid profile were measured at day 0 and day 90. One way ANOVA test was applied to find the significant difference between the groups and Tukey HSD post hoc test was applied for multiple comparisons among the four groups with probability p-value 0.05%. Multiple comparisons by post-hoc analysis between groups on day 90 showed a significant reduction of fasting blood sugar by 19.0% (p = 0.021), postprandial blood sugar by 35.0% (p= 0.001), total serum cholesterol by 14.0% (p= 0.000), serum triglyceride by 21.0% (p=0.000), and serum LDL cholesterol by 17.0% (p= 0.000)ingroup receiving Karela and fenugreek seeds supplementation. Whereas serum HDL cholesterol on the 90th day was higher in the group by 10.0% (p=0.015) receiving only fenugreek seeds as a supplementation. Fenugreek and karela, when given as a supplement, have a beneficial effect on blood sugar and lipid profile.

scholarly journals Results of a Randomized, Open-Label, Clinical Trial Investigating the Effects of Supplementation withHeracleum persicumExtract as an Adjunctive Therapy for Dyslipidemia

2011 ◽  
Vol 11 ◽  
pp. 592-601 ◽  
Author(s):  
Yunes Panahi ◽  
Bahram Pishgoo ◽  
Fatemeh Beiraghdar ◽  
Zahra Mohammadi Araghi ◽  
Amirhossein Sahebkar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Lipid Profile ◽  
Adjunctive Therapy ◽  
Serum Triglyceride ◽  
Serum Levels ◽  
Open Label ◽  
Atorvastatin Group ◽  
Heracleum Persicum ◽  
Baseline Values ◽  
Significant Change

The present study evaluated the potential benefit of supplementation withHeracleum persicumas an adjunctive therapy to atorvastatin in dyslipidemic subjects. In a randomized, open-label, clinical trial, 100 dyslipidemic subjects were randomly assigned to: (1)H. persicumgroup (n= 50, completers = 18), receivingH. persicumextract (500 mg/day) + atorvastatin (10 mg/day) for 8 weeks, or (2) atorvastatin group (n=50, completers= 34), receiving only atorvastatin (20 mg/day) for 8 weeks. Weight, body mass index (BMI), lipid profile, and biomarkers of hepatic and renal injury were determined at baseline and at the end of the trial. There were significant reductions in serum total cholesterol and LDL-C in both theH. persicum(p= 0.001) and atorvastatin (p< 0.05) groups. Serum HDL-C was elevated in the atorvastatin group (p< 0.05), while no significant change was observed in theH. persicumgroup (p> 0.05). Serum triglyceride levels remained statistically unchanged by the end of the trial in both groups (p> 0.05). Serum alanine (p= 0.049) and aspartate aminotransferase (p= 0.013) levels rose in the atorvastatin, but not theH. persicum(p> 0.05) group. In comparison with baseline values, no significant change was observed in weight and BMI, as well as serum levels of creatinine, blood urea nitrogen, and fasting blood sugar in either of the groups (p> 0.05). Apart from HDL-C, the effects of atorvastatin (20 mg/day) on other lipid profile parameters do not appear to be significantly superior to those achieved by combination therapy withH. persicum+ atorvastatin (10 mg/day).

scholarly journals Effect of lisinopril and perindopril on serum lipid profile in Albino rabbits

2018 ◽  
Vol 7 (6) ◽  
pp. 1136
Author(s):  
Shruti Chandra ◽  
S. P. Singh ◽  
Rashmi Singh ◽  
Neeraj Kumar Agarwal
Keyword(s):  
Lipid Profile ◽  
Total Cholesterol ◽  
Serum Lipid ◽  
Serum Triglyceride ◽  
Serum Lipid Profile ◽  
Favourable Effect ◽  
Serum Triglyceride Level ◽  
Group I ◽  
Group Ii ◽  
Significant Change

Background: Hypertension with dislipidemia is becoming a common morbidity, since ACE inhibitors are the first line of antihypertensive drugs so present study was undertaken with the aim to evaluate the possible effects of ACE inhibitor on lipid profile in albino rabbits.Methods: The study was conducted in the Department of Pharmacology and Therapeutics, GSVM Medical College, Kanpur. Rabbits were divided into 2 groups with 6 in each group. Rabbits of Group I was given Lisinopril in dose of 0.25mg/kg and of group II was given Perindopril in dose of 0.20mg/kg for a period of 6 weeks. Lipid profile estimation (Serum Total cholesterol, serum HDL, serum LDL, serum Triglycerides and serum VLDL) was done at day 0, 7, 21 and 45 respectively.Results: After analysis Rabbits of group-I (Lisinopril) showed 3.1% decrease in serum cholesterol level at 45th day (P<0.001). Serum HDL level increased by 6.4% and 14.3% at day 21 and 45 respectively (P<0.05). Increase in serum Triglyceride level was 2.6% at day 45 (P>0.05). Serum LDL level decreases by 4.4% and 8.6% at day 21 and 45 respectively (P<0.001). There was no significant change in Serum VLDL level. Rabbits of group- II (Perindopril) showed decreased total cholesterol levels by 2.6% (P<0.05). There was an increase in HDL level by 6.8 % at day 45(P<.05). Triglycerides and VLDL levels were not significantly altered while serum LDL level decreases by 6.7% at day 45 (P<0.01).Conclusions: From our study it was concluded that Lisinopril had a favourable effect on serum lipid profile by decreasing total cholesterol, increasing serum HDL level. It may increase triglycerides, decrease LDL. Perindopril increase serum HDL and decreases LDL, there is no significant change in cholesterol, TG and VLDL levels.

scholarly journals The Effect of Smoking on the Lipid Profile of Inhabitant Smokers of Hasilpur, District Bahawalpur, Pakistan

2020 ◽  
Vol 10 (2) ◽  
pp. 82-86
Author(s):  
Mushtaq Hussain Lashari ◽  
Sumbel Sumera ◽  
Umer Farooq ◽  
Zia Ur Rehman ◽  
Nuzhat Sial ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Serum Triglyceride ◽  
Mean Value ◽  
Heavy Smoker ◽  
Control Group ◽  
Mean Values ◽  
Significant Difference ◽  
The Mean ◽  
Control Light ◽  
Heavy Smokers

Background: Health problem are culturally associated with smoking in developing countries. Many hazardous chemicals are taken up by direct or passive smoking causing lipid peroxidation resulting in oxidative stress. Objectives: To estimate the occurrence of smoking and its effects on the lipid profile in populations of Hasilpur, Pakistan. Methodology: The current study was conducted from April - August 2014. Out of 247 apparently healthy subjects of both genders (male=220; female=27), 134 were smokers and 113 were non-smokers. In order to analyze lipid profile, blood samples were collected in early morning hours from the selected members who were asked to fast all night. By using Chem-100 chemistry analyzer, cholesterol, triglyceride, HDL, LDL and VLDL were analyzed. Results: The overall prevalence of smokers was 54.25%. The results showed 60.9% prevalence in males and 0% in females. The mean value of serum triglyceride in control, light smokers and heavy smokers was 147.4±11.7mg/dl, 190.8±41.4 and 205.3±29.7mg/dl, respectively. The results of cholesterol in control, light smokers and heavy smokers were 147.38±7.99mg/dl, 136.8 ±12. 8mg/dl and 173.44±8.63mg/dl, respectively. There was a considerable distinction in the mean level of serum triglyceride and cholesterol between the control group, light smokers and heavy smoker groups (P<00.5). The mean value of HDL of control, light smokers and heavy smokers was 30.93±1.30mg/dl, 31.10±2.45 and 34.58±1.55mg/dl, respectively. The mean values of LDL and VLDL of control, light smokers and heavy smokers were 110.46±3.63mg/dl, 106.00±4.52mg/dl, 117.19±3.48mg/dl and 33.54±3.11mg/dl, 49±9.02mg/dl, 41.06±5.34mg/dl, respectively. There was significant difference in the mean level of HDL, LDL and VLDL between the control group, light smokers and heavy smoker groups (P<0.05). Conclusion: This study concluded that smoking is the reasons of variation in the lipid profile. Elevated period of smoking and the number of smoked cigarettes/day reason the alteration in serum lipid levels and is probably related with increased danger for coronary artery disease.

Study of Lipid Profile in Diabetes Mellitus with and without Hypertension

2019 ◽  
Vol 5 (1) ◽  
pp. 31-36
Author(s):  
Jay Jha ◽  
Varun Malhotra ◽  
Om Jha ◽  
Shivani Gupta
Keyword(s):  
Diabetes Mellitus ◽  
Study Design ◽  
Serum Triglyceride ◽  
Control Group ◽  
Diabetic Patients ◽  
Serum Triglyceride Level ◽  
Balanced Diet ◽  
Significant Difference ◽  
Artery Disease ◽  
Lipid Abnormalities

Introduction Alterations in the lipid metabolism have been reported in the subject of diabetes mellitus. They may be influenced by the presence of hypertension. Aims The present study was undertaken to estimate the serum lipids profiles of diabetics with and without hypertension. Study design The study design is experimental with comparative study method, Methodology The sample size taken is 80 which is divided into four groups as A group of 20 healthy individuals of age 20-70 years, other B group of 20 diabetic patients without Hypertension, other C group of 20 hypertensive patients without diabetes and the rest 20 diabetic patients along with hypertension of age 20-70 years of D group. They were matched with respect to various lipid parameters such as total cholesterol, Triglycerides, lipoprotein ratio etc. with control group A. Place and duration of study: the study took place at Santosh group of institutions between August 2013 to August 2016. Result The serum cholesterol levels were significantly higher in hypertensives without diabetics and in diabetics with hypertension as compared to normal controls. No significant difference in the serum triglyceride level was observed among various groups in this study. The ?: ? lipoprotein ratio was found to be affected in all the groups as compared to controls with maximum ratio in diabetics without hypertension and in hypertension without diabetes. Patients who were suffering from diabetes and hypertension were at a maximum risk of developing atherosclerosisand its complications such as coronary artery disease. Diabetics with hypertension had significant higher levels of cholesterol as compared to that of without hypertension. The diabetics with hypertension had lipid abnormalities because of diabetic element in them rather than the hypertension. All the groups studied except the controls were found to be increasingly susceptible to the risk of atherosclerosis and its complications. This risk was found to be maximum in diabetics with hypertension rather than diabetics or hypertensive’s alone. Conclusion The need for right balanced diet, regular exercise and a stress free life is essential for prevention and management of diabetes and hypertension. 

scholarly journals SEVERE HYPERTRIGLYCERIDEMIA ASSOCIATED WITH EVEROLIMUS TREATMENT AFTER HEART TRANSPLANTATION

2020 ◽  
Vol 6 (5) ◽  
pp. e269-e272
Author(s):  
Phillip Lo ◽  
Katherine Kearney ◽  
Christopher A. Muir ◽  
Ning Song ◽  
John A. Eisman ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Heart Transplant ◽  
Serum Triglyceride ◽  
Adverse Outcomes ◽  
Lipid Lowering ◽  
High Dose ◽  
Serum Triglyceride Level ◽  
Post Transplantation ◽  
Partial Lipodystrophy ◽  
Severe Hypertriglyceridemia

Objective: Everolimus, a mammalian target-ofrapamycin (mTOR) inhibitor, is increasingly used post-transplantation due to favorable effects on renal function and malignancy risk when compared to other immunosuppressive treatments such as calcineurin inhibitors. However, it can confer adverse effects such as dyslipidemia, which is not underpinned by any long-term screening and management of dyslipidemia in heart transplant recipients treated with everolimus. Methods: We report a case of severe hypertriglyceridemia which developed after commencement of everolimus in a heart transplant recipient with a background of Dunnigan-type familial partial lipodystrophy. Results: The patient is a 36-year-old woman who underwent heart transplantation for dilated cardiomyopathy. About 11 weeks following commencement of everolimus as part of her antirejection medication regime, serum triglyceride level concentration peaked at 5,093 mg/dL (normal, 0.0 to 177.2 mg/dL). There were no clinical complications with triglycerides at this elevated level and it improved substantially following cessation of everolimus and initiation of a high dose intravenous insulin-dextrose infusion. Conclusion: This case highlights dyslipidemia as a potential complication of everolimus treatment and that appropriate screening is important as lipid lowering medication can effectively control levels and minimize adverse outcomes.

scholarly journals Effect of Red Raspberry (Rubus idaeus L.) Consumption With or Without Fructo-Oligosaccharide on Metabolic Indices: A Single-Blinded Randomized, Crossover Clinical Trial (OR29-03-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Xuhuiqun Zhang ◽  
Anqi Zhao ◽  
Indika Edirisinghe ◽  
Amandeep Sandhu ◽  
Britt Burton-Freeman
Keyword(s):  
Clinical Trial ◽  
Lipid Profile ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Rubus Idaeus ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Lowering Effect ◽  
Insulin Responses ◽  
Lipid Lowering Effect

Abstract Objectives Red raspberries (RRB) contain a unique polyphenol profile associated with cardio-metabolic benefits. Fructo-oligosaccharides (FOS), as prebiotics, present an approach to augment the cardio-metabolic benefits of RRB through their known effects in modifying the gut microbiota composition. The objective of this study is to determine the effect of RRB intake with or without FOS on glucose and insulin responses and fasting lipid profile in insulin-resistant (IR) (n = 20) and metabolically healthy reference (R) adults (n = 11) in a single-blinded, randomized, 12-week crossover clinical trial. Methods In this crossover study, after one-week run-in, subjects consumed RRB (1 cup RRB equivalence) or RRB + FOS (1 cup RRB equivalence with 8 g FOS) for 4 weeks in random order separated by 4-week washout between supplementation periods. Before and after each supplementation period, glucose and insulin responses were assessed by 2-h postprandial glycemic challenge with RRB (75 g glucose equivalence) and the plasma lipid profile characterized (total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and triglycerides (TG)). Results IR group had significantly elevated fasting and postprandial glucose and insulin, and higher fasting TG and lower HDL compared to R at baseline (0-week) (P ≤ 0.05); no differences in TC and LDL between groups (P > 0.05). After 4-week intervention, RRB decreased TC and LDL of IR group from baseline by 7% (P = 0.024) and 9% (P = 0.007), respectively, whereas adding FOS significantly attenuated the lipid-lowering effect of RRB. Alternatively, addingFOS to RRB augmented RRB effect on glycemic variables: 4-week intake of RRB + FOS significantly decreased 30 min incremental areas under curve (iAUC 0–30) of IR group for glucose and insulin from baseline by 20% (P = 0.014) and 18% (P = 0.012), respectively. Conclusions 4-week RRB intervention improves glycemic and lipid profiles in people with IR. Adding FOS to RRB supplement enhanced the glycemic benefits, but attenuated the lipid-lowering effect of RRB. Funding Sources This work was supported by the National Processed Raspberry Council.

scholarly journals EFFECTS OF EDAMAME (Glycine max) EXTRACTON POST-PRANDIAL SERUM TRIGLYCERIDE IN WISTAR RATS

2017 ◽  
Vol 52 (1) ◽  
pp. 57
Author(s):  
Imran H Kamal ◽  
Linda Dewanti ◽  
Rio Wironegoro
Keyword(s):  
Glycine Max ◽  
Palm Oil ◽  
Serum Triglyceride ◽  
Intragastric Administration ◽  
Serum Triglyceride Level ◽  
Test Study ◽  
Significant Difference ◽  
Post Test ◽  
Materials Used ◽  
Intragastric Tube

Edamame (Glycine max) is a preparation of immature soybeans in the pod, which is high in calcium and dietary fiber, two elements described in previous studies that could alter the level of post-prandial serum triglyceride.The purpose of this research is to analyze the effect of edamame (Glycine max) extract on post-prandial serum triglyceride in rats after intragastric administration of palm oil.The materials used in this study are palm oil, edamame extract, and ether. The design of this study is experimental post-test study design, which is a design to measure the serum triglyceride level after meal with and without Glycine max. Triglyceride is measured on each subject two times on total, first one after consumption of meal without Glycine max and the second one after consumption of meal with Glycine max. There is a washout period of 1 week between two times the samples were taken. Both results are then compared in every subject.The level of 2-hour post-prandial serum triglyceride in rats after palm oil without intragastric edamame (Glycine max) extract administration and with intragastric edamame (Glycine max) extract administration showed no significant difference. In conclusion, edamame (Glycine max) extract had no effect on 2-hour post-prandial serum triglyceride after palm oil administration via intragastric tube.

Sign in / Sign up

Export Citation Format

Share Document